Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

28 Jun 2010

Abstract excerpt

The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born with the disease each year in Africa alone. Induction of fetal hemoglobin is a validated strategy to improve symptoms and complications of this disease. The development of targeted therapies has been limited by the absence of discrete druggable targets. We developed a unique bead-based strategy for the identification of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20616024
DOI: 10.1073/pnas.1006774107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseasePMID 20616024Read ↗

Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2Semantic proximity Read ↗

Targeted Therapeutic Strategies for Fetal Hemoglobin InductionSemantic proximity Read ↗

Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell diseaseSemantic proximity Read ↗

Recent Advances in the Treatment of Sickle Cell DiseaseSemantic proximity Read ↗

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell DiseaseSemantic proximity Read ↗

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Semantic proximity Read ↗

Regulation of the fetal hemoglobin silencing factor BCL11ASemantic proximity Read ↗

Dissecting the epigenetic regulation of the fetal hemoglobin genes to unravel a novel therapeutic approach for β-hemoglobinopathiesSemantic proximity Read ↗

Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferationSemantic proximity Read ↗

The future of sickle cell disease therapeutics rests in genomicsSemantic proximity Read ↗

Developing a pill to treat sickle cell diseaseSemantic proximity Read ↗

A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.